Acquired thrombotic thrombocytopenic purpura

DOI PDF 1 Citations

Bibliographic Information

Other Title
  • Development of an autoimmune response

Search this article

Description

<jats:title>Summary</jats:title><jats:p>The von Willebrand factor (VWF)-cleaving metalloprotease, ADAMTS13 (a disintegrin and metalloprotease with thrombospondin type 1 motifs-13) is the only known target of the dysregulated immune response in acquired TTP. Autoantibodies to ADAMTS13 either neutralize its activity or accelerate its clearance, thereby causing a severe deficiency of ADAMTS13 in plasma. As a consequence, size regulation of VWF is impaired and the persistence of ultra-large VWF (ULVWF) multimers facilitates micro vascular platelet aggregation causing microangiopathic haemolytic anaemia and ischaemic organ damage. Autoimmune TTP although a rare disease with an annual incidence of 1.72 cases has a mortality rate of 20% even with adequate therapy.</jats:p><jats:p>We describe the mechanisms involved in ADAMTS13 autoimmunity with a focus on the role of B- and T-cells in the pathogenesis of this disorder. We discuss the potential translation of recent experimental findings into future therapeutic concepts for the treatment of acquired TTP.</jats:p>

Journal

  • Hämostaseologie

    Hämostaseologie 33 (02), 121-130, 2013

    Georg Thieme Verlag KG

Citations (1)*help

See more

Keywords

Details 詳細情報について

Report a problem

Back to top